Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. corolla

CORolla

"CORolla® - a disruptive ""spring like"" metallic device for permanent treatment of diastolic heart failure."

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 CORolla project word cloud

Explore the words cloud of the CORolla project. It provides you a very rough idea of what is the project "CORolla" about.

reg    invasive    sales    health    aligns    start    heart    animals    diastole    interatrial    filling    treatment    implanted    contraction    planning    ventricular    drugs    occurs    minimally    families    inside    instrumental    procedure    elastic    augmentation    more    economic    shunting    older    device    people    frame    patients    trajectory    perfectly    cardiovascular    self    ec    corassist    life    women    complete    validation    effect    manages    trial    2    left    accounting    sme    congestive    humans    prevalence    population    systole    market    though    internal    diastolic    hf    expanding    dynamics    time    form    world    financial    needing    function    first    25    preserved    paragon    ejection    fraction    metallic    augment    social    grant    19    releases    impaired    clinical    corolla    harnesses    million    total    4    national    ago    topcat    vision    hfpef    representing    individuals    introduces    solution    globally    company    aging    trials    treat    65    instrument    threatening    relaxation    energy    spring    2021    annually   

Project "CORolla" data sheet

The following table provides information about the project.

Coordinator		 CORASSIST CARDIOVASCULAR LTD 

Organization address
address: 114TH MORIYA AVE
city: HAIFA
postcode: 3461805
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Israel [IL]
 Project website https://www.corassist.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CORASSIST CARDIOVASCULAR LTD IL (HAIFA) coordinator 50˙000.00

Map

 Project objective

Heart Failure with preserved ejection fraction (HFpEF) is a life-threatening form of congestive heart failure condition annually affecting more than 25 million people globally. HFpEF occurs commonly in older individuals and has higher prevalence in women. As the European population is aging (over 65 accounting for 19.2% of the total European population, 2.4% more than 10 years ago), HFpEF will affect more and more people, representing significant economic and social challenge for the patients, their families and National Health Systems.

Currently there is no solution on the market for such heart failure condition. Though the effect of some drugs used in the treatment of HF with reduced ejection fraction are currently studied for HFpEF in large clinical trials (e.g. PARAGON-HF Trial, TOPCAT Study), a new approach based on the left interatrial shunting is needed.

The CorAssist introduces a “spring-like” metallic device, CORolla® for augmentation of diastolic function of the heart. The CORolla® is implanted inside the left ventricular of the heart in a minimally invasive procedure. The self-expanding, internal device harnesses the elastic energy during systole (contraction) state and releases it during diastole (relaxation) in order to augment dynamics of left ventricular relaxation and filling. CORolla® manages to impact directly and improve the impaired diastolic function, needing only one-time procedure.

CorAssist Cardiovascular has the vision to become the first company in the world to treat HFpEF. The EC grant is instrumental to this ambitious goal and company’s growth trajectory. Following a very promising validation in animals and humans, the company is planning to start first sales of CORolla® by the end of 2021.The SME Instrument project perfectly aligns with this objective, as it would provide the company with the financial resources necessary to complete the clinical study within the planned time-frame.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COROLLA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COROLLA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More